• Explore /
  • Poster
  • / A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.

A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.

Abstract Poster

Authors

null

Anthony W. Tolcher

NEXT Oncology, San Antonio, TX

Anthony W. Tolcher , Xiaohua Wu , Jian Zhang , Minal A. Barve , Nashat Y. Gabrail , David Sommerhalder , Ildefonso I Rodriguez Rivera , Sharon Wilks , Yong Wu , Rujiao Liu , Shuiping Gao , Akhilkrishna Valiyil , Ntombizodwa Sayi , Caroline Germa , Charlie Qi , LEI Chen , Steven Yu , Jenny Yao , Xuelian Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Clinical Trial Registration Number

NCT04958434

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2531)

DOI

10.1200/JCO.2023.41.16_suppl.2531

Abstract #

2531

Poster Bd #

373

Abstract Disclosures

Similar Posters

First Author: Miaozhen Qiu

Poster

2020 ASCO Virtual Scientific Program

Quilt-3.064: An open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers.

Quilt-3.064: An open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers.

First Author: Tara Elisabeth Seery

First Author: Karen Kelly

First Author: Iwona A. Lugowska